COEP (Coeptis Therapeutics Holdings) LT-Debt-to-Total-Asset: 0.01 (As of Dec. 2025)


COEP Coeptis Therapeutics Holdings Inc COEP
12 GF Score
Price $16.40
View Full Analysis

What is Coeptis Therapeutics Holdings LT-Debt-to-Total-Asset?

Coeptis Therapeutics Holdings COEP +1.52% 12 LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus rates COEP with a GF Score™ of 12/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Coeptis Therapeutics Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.01.

Coeptis Therapeutics Holdings's long-term debt to total assets ratio declined from Dec. 2024 (0.02) to Dec. 2025 (0.01). It may suggest that Coeptis Therapeutics Holdings is progressively becoming less dependent on debt to grow their business.

Coeptis Therapeutics Holdings  (NAS:COEP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Coeptis Therapeutics Holdings LT-Debt-to-Total-Asset Related Terms

Coeptis Therapeutics Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Coeptis Therapeutics Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coeptis Therapeutics Holdings LT-Debt-to-Total-Asset Chart

Coeptis Therapeutics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.24 0.02 0.05 0.02 0.01

Coeptis Therapeutics Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.01 0.01 0.01
COEP
12GF Score
Coeptis Therapeutics Holdings Inc COEP
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coeptis Therapeutics Holdings LT-Debt-to-Total-Asset Calculation

Coeptis Therapeutics Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.15/16.154
=0.01

Coeptis Therapeutics Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=0.15/16.154
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Coeptis Therapeutics Holdings (COEP) has a LT-Debt-to-Total-Asset of 0.01 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Coeptis Therapeutics Holdings and its competitors.
Is Coeptis Therapeutics Holdings' LT-Debt-to-Total-Asset too high?
Coeptis Therapeutics Holdings' current LT-Debt-to-Total-Asset is 0.01. Overall, Coeptis Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Coeptis Therapeutics Holdings' LT-Debt-to-Total-Asset compare to ANIX and COYA?
Coeptis Therapeutics Holdings' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Coeptis Therapeutics Holdings and its competitors. Coeptis Therapeutics Holdings's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coeptis Therapeutics Holdings stock overvalued right now?
Coeptis Therapeutics Holdings (COEP) has a current LT-Debt-to-Total-Asset of 0.01. The current LT-Debt-to-Total-Asset is 0.01. Coeptis Therapeutics Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Coeptis Therapeutics Holdings (COEP), the current LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coeptis Therapeutics Holdings Business Description

Address 105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
12GF Score

Get the complete analysis for COEP

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.40
Price